IP Library Granted Patent US 8,505,730
Granted Patent B2
US 8,505,730 · App. 13/593,184 · Granted Aug 13, 2013

Compositions, kits and regimens for the treatment of skin, especially décolletage

Inventors: Jose E. Ramirez (Key West, FL); Joseph R. Faryniarz (Middlebury, CT)
Assignee: JR Chem, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,505,730
App. No.
13/593,184
Granted
Aug 13, 2013
Kind
B2
Abstract

Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.

Claims (15)

1. A kit comprising:

a first container containing a first composition comprising a retinoid and a dermatologically or pharmaceutically acceptable carrier,

a second container containing a second composition comprising a hydroquinone and a dermatologically or pharmaceutically acceptable carrier,

a third container containing a third composition comprising a multi-metal complex and a dermatologically or pharmaceutically acceptable carrier wherein the multi-metal complex comprises a central unit, wherein the central unit is derived from at least one compound selected from polycarboxylic acids and amino acids having at least two carboxylic acid groups and the center unit bridges one or more copper molecules and one or more zinc molecules by coordinate bonding,

the first, second and third containers being enclosed within a common outer packaging, and

instructions directing a user to apply each of the first, second and third compositions to a non-facial area of the skin of a user.

2. The kit according to claim 1 , wherein the area of non-facial skin is the décolletage.

3. The kit according to claim 1 , wherein the instructions direct the user to sequentially apply the first and the second compositions to the area of non-facial skin.

4. The kit according to claim 1 , wherein the instructions direct the user to simultaneously apply the first and the second compositions to the area of non-facial skin.

5. The kit according to claim 1 , wherein the retinoid is retinol or tretinoin.

6. The kit according to claim 1 , wherein the hydroquinone is arbutin.

7. The kit according to claim 1 wherein the instructions direct the user to: a) apply the first, second and third compositions as a first treatment; b) wait a pre-determined period of time; and c) apply the second and third compositions as a second treatment.

8. The kit according to claim 7 , wherein the instructions direct the user to wait at least four hours between the first treatment and the second treatment.

9. The kit according to claim 7 , wherein the instructions direct the user to perform the first treatment in the morning and the second treatment in the evening.

10. The kit according to claim 7 , wherein the instructions direct the user to pre-mix the first and the second compositions immediately prior to administering the first treatment to the area of skin.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0092 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0475 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0506 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0718 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2014
From: JR CHEM, LLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 032110/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2014
From: FARYNIARZ, JOSEPH R.; RAMIREZ, JOSE E.
To: JR CHEM, LLC
Reel/Frame 032093/0538 →
Continuity (3)
Division 12331781 · Dec 10, 2008
Provisional Application 61019047 · Jan 4, 2008
Related Publication 20120312717A1 · Dec 13, 2012